Lisocabtagene maraleucel received approval from the U.S. Food and Drug Administration (FDA) on February 5, 2021.

Voclosporin was approved by the U.S. Food and Drug Administration (FDA) on January 22, 2021.

Vericiguat received approval from the U.S. Food and Drug Administration (FDA) on January 19, 2021.

Ansuvimab-zykl (Ebanga) was approved by the US Food and Drug Administration (FDA) on December 21, 2020, for the treatment of Zaire ebolavirus infection in both adults and pediatric patients.

Margetuximab was approved by the US Food and Drug Administration (FDA) on December 16, 2020, for the treatment of metastatic HER2-positive breast cancer in combination with chemotherapy.

Tirbanibulin, marketed under the brand name Klisyri, is a topical ointment used primarily to treat actinic keratosis.

Berotralstat received approval from the US Food and Drug Administration (FDA) on December 3, 2020.

Setmelanotide received FDA approval on November 25, 2020. The approval was granted for the treatment of obesity caused by rare genetic disorders.

Naxitamab received accelerated approval from the U.S. Food and Drug Administration (FDA) on November 25, 2020.

Casirivimab and Imdevimab received Emergency Use Authorization (EUA) from the FDA on November 21, 2020.

Approved on November 20, 2020, it offers a vital treatment option for managing these rare genetic conditions.

Approved on October 14, 2020, it provides a crucial option for managing and treating Ebola virus disease.